Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MASS syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    574 result(s) found for: MASS syndrome. Displaying page 1 of 29.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-009155-37 Sponsor Protocol Number: 2008/066/HP Start Date*: 2010-09-07
    Sponsor Name:CHU-HOPITAUX DE ROUEN
    Full Title: Evaluation of the impact of physical reconditioning associated with specific nutritional supplementation in obese patients suffering of metabolic syndrome.
    Medical condition: Obese patients suffering of metabolic syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000660-33 Sponsor Protocol Number: ZAF-312 Start Date*: 2015-09-30
    Sponsor Name:Zafgen Inc.
    Full Title: Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of Beloranib in Obese Subjects with Prader-Willi Syndrome to Evaluate Food-related Behavior, Total Body Weight, and Safety Over 52 Weeks
    Medical condition: Improvement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004867-65 Sponsor Protocol Number: CAFQ056B2154 Start Date*: 2012-02-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Sequential, two-period study to assess the pharmacokinetics, safety & tolerability of single and multiple oral doses of AFQ056 in patients with FXS (Fragile X syndrome) aged 5-11 years (Cohort 1) a...
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019353-18 Sponsor Protocol Number: CAFQ056B2131 Start Date*: 2011-10-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A sequential, open-label, two-period study to assess the pharmacokinetics, safety and tolerability of two dose levels of AFQ056 in male, adolescent patients with Fragile X Syndrome (12 to 18 years ...
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003537-16 Sponsor Protocol Number: PR3084 Start Date*: 2008-09-04
    Sponsor Name:Erasmus MC
    Full Title: Estetrol Therapy in Sjogren's Syndrome: An Open Proof of Concept Study
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040767 Sjogren's syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003392-10 Sponsor Protocol Number: CMEK162Y2201 Start Date*: 2012-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy.
    Medical condition: Noonan syndrome hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    14.1 10007541 - Cardiac disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-003062-13 Sponsor Protocol Number: AZP01-CLI-003 Start Date*: 2020-02-25
    Sponsor Name:Millendo Therapeutics SAS
    Full Title: A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome
    Medical condition: Prader-Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004447-35 Sponsor Protocol Number: version 1, 05/08/2006 Start Date*: 2006-09-20
    Sponsor Name:Hull and East Yorkshire Hospital Trust
    Full Title: Biological Variation of Insulin Resistance, Testosterone and Cardiovascular Risk Factors In Women with Polycystic Ovarian Syndrome: modification with Rimonabant compared to Metformin.
    Medical condition: Patients with Polycystic Ovary Syndrome and body mass index above 30 kg/m2
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036049 Polycystic ovaries LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004430-96 Sponsor Protocol Number: 201600107 Start Date*: 2017-12-11
    Sponsor Name:University Medical Center Groningen
    Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk
    Medical condition: Testicular cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002542-33 Sponsor Protocol Number: ZYN2-CL-033 Start Date*: 2022-02-22
    Sponsor Name:Zynerba Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndro...
    Medical condition: Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 ge...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006991-31 Sponsor Protocol Number: UOE/08/03 Start Date*: 2009-06-11
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Effect of the combined treatment with myo-inositol and metformin on the phenotype of the polycystic ovary syndrome: a pilot study
    Medical condition: polycystic ovary syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036049 Polycystic ovaries LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003923-40 Sponsor Protocol Number: APHP200019 Start Date*: 2021-01-08
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
    Full Title: A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ...
    Medical condition: Sepsis complicated by ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002477-45 Sponsor Protocol Number: ERX_01_05 Start Date*: Information not available in EudraCT
    Sponsor Name:ErgoNex Pharma GmbH
    Full Title: A randomized, double-blind, placebo-controlled, multicenter evaluation of the efficacy and safety of terguride tablets, administered orally for 3 months, to patients with fibromyalgia.
    Medical condition: fibromyalgia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10048439 Fibromyalgia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000647-14 Sponsor Protocol Number: 15782601 Start Date*: 2016-05-23
    Sponsor Name:University Hospital Toulouse
    Full Title: Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial
    Medical condition: Noonan syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004262-35 Sponsor Protocol Number: RGH-706-003 Start Date*: 2022-08-29
    Sponsor Name:Gedeon Richter Plc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
    Medical condition: Prader-Willi syndrome (PWS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000250-22 Sponsor Protocol Number: CVAY736X2201 Start Date*: 2014-04-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single dose, double-blind, placebo-controlled, parallel study to assess the pharmacodynamics, pharmacokinetics and safety and tolerability of VAY736 in patients with primary Sjögren’s syndrome
    Medical condition: Seropositive primary Sjögren’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002966-34 Sponsor Protocol Number: TAK-861-2002 Start Date*: 2023-03-20
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2)
    Medical condition: Narcolepsy without Cataplexy (Type 2)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) FR (Completed) IT (Completed) ES (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-004383-37 Sponsor Protocol Number: SP1004 Start Date*: 2015-04-08
    Sponsor Name:UCB BIOSCIENCES, Inc.
    Full Title: A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10058920 Restless legs syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004797-18 Sponsor Protocol Number: Start Date*: 2017-06-26
    Sponsor Name:Imperial College London
    Full Title: Pilot study of the GLP-1 agonist, Liraglutide, on decreasing parenteral support requirements in short bowel patients.
    Medical condition: Intestinal failure with an underlying aetiology of short bowel
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-004497-15 Sponsor Protocol Number: ERGO Start Date*: 2016-12-12
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in C...
    Medical condition: Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 05:54:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA